• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Reed-Lane

    Quotient Sciences

    PCI Pharma Services

    Emergent BioSolutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Syngene

    Alcami

    Reed-Lane
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Injectable Drug Delivery Trends

    How medication trends are driving the shift to patient-friendly drug delivery systems.

    Injectable Drug Delivery Trends
    Injectable Drug Delivery Trends
    Figure 1. Market Share by RoA
    Injectable Drug Delivery Trends
    Figure 2. Global Market-shaping Trends
    Injectable Drug Delivery Trends
    Peter Soelkner, Managing Director at Vetter
    Related CONTENT
    • Obituary Notice: Russell “Russ” Haines
    • Recro, Ensysce Expand Development and Manufacturing Partnership
    • Executive Moves: Novavax
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate
    Peter Soelkner, Managing Director, Vetter03.01.21
    When biopharmaceutical companies start development of a new parenteral product, their strategic manufacturing partners often encourage them to follow one key dictum: start with the end in mind.

    Recently, however, the ends these companies must plan for have undergone considerable shifts. Major global medication trends are driving a sea change in the lifecycle goals that companies must plan for when developing a new parenteral product. Many of these trends are already leading to a major realignment of priorities for new drug products, including the way they need to evolve across their lifecycle.

    While the potency and efficacy of the drug substance itself remain vital, shifting patient needs and expectations are now driving the need to further improve the patient-friendliness of every product attribute—in ways that not only support product efficacy, but also the safety, convenience, compliance, and market differentiation of new injectable products.   

    Growing market, changing goals
    Parenteral products are a major growth engine in today’s surging global biopharma market. Figure 1 shows their share of the global market is expected to grow from 52% in 2019 ($604bn) to 55% in 2026 ($1,206bn), outpacing other routes of administration.1 On average, more than 40% of the medications approved by the FDA are injectable, with subcutaneous and intramuscular products making up a growing percentage of those approvals.2,3 


    Figure 1. Market Share by RoA

    Even in this fast-growing market, though, successful new parenteral medications need more than a promising molecule and a validated therapeutic target. They need a clear, complete picture of the clinical, commercial, logistic, and operational factors that define the product’s pathway to success. Specified, agreed-upon market requirements, target product attributes, and commercial goals are as critical as the drug substance and its mechanism of action—not to mention the injectable delivery system that will be used to administer that new treatment.

    Defining these parameters at the start has always been a critical first step in creating a truly integrated, efficient, and resilient drug development and manufacturing process. It’s an increasingly vital step today. Not because these critical success factors have changed—it’s as important as ever to define a product’s key attributes and requirements from the very beginning—but because many of the end goals have. The key features of the roadmap remain the same. But for many high-value parenteral medications, the potential destinations have shifted dramatically.

    Market-shaping trends
    A new injectable biopharma product that enters the pipeline today will launch into a market that’s evolving rapidly, in ways that are quickly redefining the typical use cases for new parenteral drugs and their delivery systems.

    There are four major global trends that are driving this transformation: Chronic disease, development costs, at-home-care and COVID-19 (see Figure 2).


    Figure2. Global Market-shaping Trends.

    Chronic disease
    Conditions like diabetes, heart disease, Alzheimer’s, and COPD are rapidly growing in both global prevalence and economic impact. As the incidence of these diseases continues to increase, the sustained, intensive treatment patients require will place increasingly significant demands on the resources of the global health system.

    Development costs
    Demand for specialized, targeted, and personalized treatments—as well as the complex processes and often much smaller batch sizes they require—continues to spike the level of investment needed to bring new treatments to market. As more and more sensitive, highly customized biologics enter the global pipeline, their biopharma owners are under growing pressure to optimize costs and shorten timelines wherever possible.

    At-home care
    One major cost-saving strategy has become increasingly important: shifting patient care out of resource-intensive clinical settings and into patients’ homes. At-home care lightens provider workloads, reduces demand for expensive clinical services, and offers greater convenience for patients and caregivers. Not surprisingly, many biopharma companies have begun to proactively target this valuable use case in their product development strategies.

    COVID-19
    All of these trends have been accelerated by the global pandemic. Flooded by COVID cases, many thinly stretched health systems are now ever-more focused on remotely managing as many conditions as possible—while patients themselves are increasingly eager to stay home as much as possible. Both the challenges and opportunities produced by this shift are further increasing the pressure on biopharma companies to not only launch new treatments faster and more efficiently than ever, but also enhance those new products with features that make self-administered treatment as safe, effective, and convenient as possible. 

    Together, these trends are shaping a transformative new reality for the biopharma market. The target profile for tomorrow’s high value injectable has changed: from an efficacious molecule with a familiar, go-to injection method, to a complex, customized treatment with a delivery system optimized for convenient, long-term self-delivery at home.

    Delivery innovations for changing demands
    For today’s injectable drug owners, “starting with the end in mind” no longer means simply planning for a successful initial commercial launch. Today’s market is thirsty for products that not only deliver therapeutic benefits, but that are also designed to provide an easy, safe, adherence-supporting delivery experience. To create such a product, drug owners need to think far beyond the molecule, its therapeutic target, and launch configuration. New injectables now need to hit the market with a full-lifecycle development plan to continually enhance the product’s convenience and patient-friendliness.

    One key to that ongoing enhancement is often the product’s packaging and delivery system. Today’s drug development plans can already factor in a rapidly growing range of innovations in these areas. Several of these products have already shown that they can deliver significant value-adding differentiation of a parenteral product’s user experience:

    Prefilled syringes
    Prefilled syringes are a user-friendly option that makes it easy and safe to deliver each dose—a significant differentiating value. Drug products in this ready-to-inject format offer patients a simple, comfortable administration process with predefined volumes, often also resulting in improved compliance.

    Pens and autoinjectors
    Convenient, compact, and easy to handle, these secondary packaging innovations can be a useful way to facilitate long-term self-administration – especially for patients whose condition may compromise their physical dexterity.

    Wearables
    Numerous treatments that require a specific, uniform amount of medication can be delivered via innovative clip- and stick-on parenteral delivery systems. These convenient devices enable consistent dosing of large product volumes, while also fitting discretely into a patients’ outfit and lifestyle.

    Connected smart devices
    Pharma 4.0 is driving the convergence of injection systems and information systems, including a new generation of connected autoinjectors, infusion pumps, and other drug delivery technologies that combine personalized dosing with data capture and reporting capabilities. These delivery systems not only simplify dosing, but also offer providers and patients a new level of digital visibility and insight into each course of treatment. 

    These diverse innovations have a common benefit. They’re designed to make long-term injectable treatments simpler, more convenient, and more manageable for the patients who need them, and who are likely to be administering their treatment themselves. As global trends continue to accelerate the shift toward products optimized for patient-friendliness, we anticipate that innovations like these will play an increasingly important goal in product lifecycle plans developed for new injectables. A successful launch in a vial may only be a first step, one that may often be followed by many future evolutions designed to optimize patients’ administration experience.   

    Increasing value of strategic partners
    New parenteral products can factor a variety of different delivery innovations into the product’s lifecycle. But while these solutions can contribute significant value to a product’s market profile, they also add another dimension that’s equally important to consider and solve: production complexity. 

    The global shift toward patient-friendly delivery systems has increased the level of manufacturing sophistication required to sustain the continual evolution of a product’s market profile. A high-quality fill-and-finish plan is only one step in the production of a high-value parenteral product. The same development plan must now also show a clear pathway to several different evolutions of the product’s secondary packaging, each with its own regulatory requirements, quality standards, and manufacturing specifications.

    For biopharma companies and their injectable products, this new paradigm means that the right strategic production partners are now more valuable than ever. Today’s clinical and commercial teams need far more than a service provider who can handle drug product manufacturing. They need production experts who can provide multifaceted technical expertise, solution customization, and market foresight—not just prior to and at launch, but across the product lifecycle. These vital partners will not simply encourage biopharma companies to start with the end in mind. They’ll be there to help those companies navigate the continuing, dynamic evolution of those ends, as patient needs and market drivers continue to reshape the highest-value goals for new injectable products.

    Summary
    A new generation of high-value injectable products is already taking shape in response to major concurrent trends in the global biopharma market. These products not only deliver safe, efficacious, long-term treatment, but are also setting new standards for safe, accurate, convenient self-administration.

    These advanced injectables will create both new opportunities and new challenges for their owners. As chronic conditions become more prevalent and patient care increasingly shifts from the clinic to the home, meeting the needs of this changing market will require drug owners to deliver new injectable products that combine both clinical efficacy and differentiating administration experiences. It’s time for biopharma companies to factor this significant added complexity into their product development plans. The first step: finding the right development and manufacturing partners. Ones with proven experience in putting new injectables on a path to success from the start. 

    References
    1. Global Data Sales Analytics, 24 June 2020
    2. FDA.gov
    3. ibid


    Peter Soelkner has been a Managing Director of Vetter Pharma-Fertigung GmbH & Co. KG since June 2008. In 2009, he was also appointed Managing Director of Vetter Pharma International GmbH, the company’s marketing and sales organization. Soelkner graduated from the University of Dortmund, Germany, in 1992 with a degree in chemical engineering and earned an MBA from Columbia University, New York, in 2001. Before joining Vetter, he held positions in Germany and North America at Sartorius AG and Sartorius North America Inc., in R&D, marketing, key account management, and general management roles. At Vetter, from 2003 to 2007, Soelkner managed the company’s key account program and global end-to-end supply chain. He left the company for a year to serve as Vice President of global key account management at Sartorius Stedim Biotech (USA) before returning to Vetter in 2008.
    Related Searches
    • Drug Delivery
    Suggested For You
    Obituary Notice: Russell “Russ” Haines Obituary Notice: Russell “Russ” Haines
    Recro, Ensysce Expand Development and Manufacturing Partnership Recro, Ensysce Expand Development and Manufacturing Partnership
    Executive Moves: Novavax Executive Moves: Novavax
    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate Kindeva Drug Delivery and Cambridge Healthcare Innovations Collaborate
    PharmParts – This Makes Sense! PharmParts – This Makes Sense!
    RBQM Comes of Age: COVID as a Catalyst for Change RBQM Comes of Age: COVID as a Catalyst for Change
    Fast Track Automation in Pharmaceutical Manufacturing Fast Track Automation in Pharmaceutical Manufacturing
    Jubilant HollisterStier, Lilly Enter Bamlanivimab Mfg. Pact Jubilant HollisterStier, Lilly Enter Bamlanivimab Mfg. Pact
    Cassava Sciences Enters Drug Supply Agreement with Evonik Cassava Sciences Enters Drug Supply Agreement with Evonik
    FDA Grants Tentative Approval to Generic Version of Symbicort FDA Grants Tentative Approval to Generic Version of Symbicort
    Cytovance Biologics Offers Licensing for Plasmid DNA Manufacturing Cytovance Biologics Offers Licensing for Plasmid DNA Manufacturing
    Sharp Appoints EU Qualified Person Sharp Appoints EU Qualified Person
    Jubilant Therapeutics Appoints Chief Scientific Officer Jubilant Therapeutics Appoints Chief Scientific Officer
    Iontas and Fair Journey Biologics Partner with Quell Therapeutics Iontas and Fair Journey Biologics Partner with Quell Therapeutics

    Related Features

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Development and manufacture of medicated chewing gum continues to gain momentum.
      Rukayat Adedeji, Contributing Writer 03.01.21


    • Drug Delivery
      Inhaled Drug Delivery Technology

      Inhaled Drug Delivery Technology

      The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20

    • Drug Delivery
      Wet Wipes Increased Prevalence in Drug Development

      Wet Wipes Increased Prevalence in Drug Development

      A number of factors including patient preference are driving the growth of wet wipes in pharma.
      John Waddell, Business Development Director – Pharma, PDI Contract Manufacturing 10.14.20


    • Drug Delivery
      Not Your Father’s Oral Thin Film

      Not Your Father’s Oral Thin Film

      A look at how oral film drug delivery is evolving.
      Rodolphe Obeid, Vice President of Operations, IntelGenx 06.04.20

    • Drug Delivery | Regulatory Affairs
      Regulatory Overhaul for Medical Devices

      Regulatory Overhaul for Medical Devices

      Implications for the pharmaceutical industry.
      Elizma Parry, Director, Global Clinical Practice, Maetrics 06.04.20

    • Drug Delivery
      CEO Spotlight: Will Downie

      CEO Spotlight: Will Downie

      Vectura’s chief executive talks trends in the inhaled-drug market, and the company’s transition into a CDMO
      Tim Wright, Editor, Contract Pharma 04.01.20


    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19

    • Drug Delivery
      Nasal Drug Delivery

      Nasal Drug Delivery

      A look at best practices for testing nasal drug delivery devices
      Maria Smith, senior manager & Charles Shaw, scientific advisor, Renaissance Lakewood LLC 01.25.19

    • Drug Delivery | Drug Development
      Traveling Toward the Intersection of Drug Development and Delivery

      Traveling Toward the Intersection of Drug Development and Delivery

      Overcoming the challenges of delivering drugs to patients.
      Louise Righton, Global Marketing Operations Manager, 3M Drug Delivery Systems 06.12.18


    • Drug Delivery | Solid Dosage/Creams/Ointments
      FDCs on the Rise

      FDCs on the Rise

      Fixed-dose combination drugs continue to gain traction due to a multitude of benefits they offer, including speed to market a
      Betsy Louda, Associate Editor, Contract Pharma 03.09.18

    • Drug Delivery
      The Future of Inhaled Medications and Inhalation Technology

      The Future of Inhaled Medications and Inhalation Technology

      Formulations, devices and strategy through non-clinical development
      Simon Moore, Envigo 10.11.17

    • Drug Delivery
      Digital Drug Delivery: A Snapshot in Time

      Digital Drug Delivery: A Snapshot in Time

      Technology is transforming the future of drug delivery
      Sam Van Alstyne, 3M Drug Delivery Systems 10.11.17

    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Executive Moves: Novavax
    • Bristol Myers Squibb Expands At Cambridge Crossing
    • Ensuring Pharma Manufacturing Quality
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    Evonik Highlights Solutions for Malodor Reduction
    P&G Emphasizes Small Actions at Home To Be More Sustainable
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login